Precision radiation boosts fight against deadly brain tumors

NCT ID NCT04574856

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether giving a higher, more targeted dose of radiation—guided by advanced MRI scans—along with standard chemotherapy (temozolomide) can improve survival in 30 people with newly diagnosed glioblastoma, an aggressive brain cancer. The radiation is adapted during treatment to hit the most resistant parts of the tumor. The main goal is to see if more people are alive at 12 months compared to usual care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Temozolomide chemotherapy and dose-intensified radiotherapy
What this could lead to
If successful, this approach could extend survival for people with newly diagnosed glioblastoma by targeting treatment-resistant tumor areas more precisely.
What could go wrong
This is a small, early-phase study (30 participants) without a comparison group, so results may not apply broadly. The intensified radiation also carries risks of increased side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.